Importantly, restoration of m6A methylation via suppression of Fto ameliorated the arrhythmic phenotype, supporting a causal role for m6A dysregulation in age‐induced AF and highlighting the therapeutic potential of targeting the m6A pathway in treating aging‐related AF. The gene discussed is FTO; the disease is atrial fibrillation.